MRKMerck Sharp & Dohme LLCFinished
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
High-grade Serous Ovarian Carcinoma · Ovarian Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 160 (final count)
- Started
- Jul 25, 2022
- Main results expected
- Dec 20, 2023
- Fully finished
- Oct 16, 2024
- Results posted
- Dec 17, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA)
Measured over: Baseline and Week 7
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05446870 · record last updated 2025-10-01 · checked 2026-11-09 15:47 UTC